Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma

noticia |

McKay R.R., Lin X., Perkins J.J., Heng D.Y.C., Simantov R., Choueiri T.K.

European Urology 2014 66:3 (502-509)

Background Bone metastases (BMs) are frequently present in patients with metastatic renal cell carcinoma (mRCC) and cause significant morbidity. Objective The purpose of this analysis was to assess the impact of BMs and bisphosphonate therapy (BT) on outcomes in mRCC. Design, setting, and participants We conducted a pooled analysis of patients with mRCC treated from 2003 to 2011 in phase 2 and 3 trials. Outcome measurements and statistical analysis Statistical analyses were performed using Cox regression and the Kaplan-Meier method. Results and limitations We identified 2749 patients treated with sunitinib (n = 1059), sorafenib (n = 355), axitinib (n = 359), temsirolimus (n = 208), temsirolimus plus interferon-? (IFN-?) (n = 208), or IFN-? (n = 560), with 28% (n = 781) having BMs. A total of 285 patients (10.4%) received BT. The presence of BMs in patients was associated with shorter overall survival (OS) when compared with patients without BMs (13.2 vs 20.2 mo, respectively; p < 0.0001) and shorter progression-free survival (PFS) (5.1 vs 6.7 mo, respectively; p < 0.0008)…(ver más)

Valora esta noticia

1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)
Loading...